Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers

NCT04512963 is registered in ClinicalTrials.gov with PRG Science & Technology Co., Ltd. as lead sponsor.

NCT NCT04512963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04512963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers
Lead sponsor
PRG Science & Technology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 24, 2020
Completion date
July 27, 2021
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hutchinson-gilford progeria syndrome, werner syndrome